Eurofins enters Japanese Genomics market by taking a stake in Fasmac
Brussels/Nantes, July 7, 2006
Eurofins has recently become one of the major shareholders in Fasmac Co. Ltd. located in Kanagawa, Japan. This allows the Group to enter into the Japanese Genomics markets.
Fasmac (an abbreviation for Food Assessment and Management Center), a subsidiary of Nippon Flour Mills Co., is the leading GMO testing laboratory in Japan as well as a producer of high purity oligonucleotides. All the oligonucleotides for the Japanese standard GMO testing methods are provided from Fasmac in its role as operator of the patent for the Japanese Standard Method. Nippon Flour Mills, listed at the Tokyo stock exchange, is the second largest Japanese industrial flour miller and producer of flour-related products for industrial, food service, and domestic uses.
Fasmac is the exclusive licensee of Eurofins | GeneScan in Japan. Eurofins is Fasmac's exclusive licencee in the USA. Fasmac will be able to use the proven analytical procedures developed by Eurofins | GeneScan and intends to deliver the full range of Eurofins| GeneScan's PCR products and services directly to the Japanese market.
It is planned that Eurofins will increase its stake in Fasmac over time. Initially, Fasmac will not be fully consolidated in the Eurofins Scientific accounts due to the percentage of Eurofins' shareholding.
For further information please visit www.eurofins.com or contact:
Investor Relations |
|
|---|---|
|
Dr. Stefan Eckhoff (International Investor Relations) Tél : +32-2-766 16 20 E-mail : ir@eurofins.com |
Hugues Vaussy (Investor Relations France) Tél: +33-(0)2-51 83 21 00 E-mail: irFrance@eurofins.com |
Notes for the editor:
Eurofins - a global leader in bio-analysis
Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors.
With over 3,500 staff in more than 50 laboratories across 13 countries, Eurofins offers a portfolio of over 10,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to provide its customers with high quality services, accurate results in time and, if requested, expert advice by our highly qualified staff.
The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy and expand both, its technology portfolio and its geographic reach. Through R&D, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international player in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on Euronext in the Paris (ISIN FR0000038259) and Frankfurt (WKN 910251) Stock Exchanges (Reuters EUFI.LN, Bloomberg ERSC FP, ESF, EUFI.DE).
Important disclaimer:
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.